Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 674.00
Bid: 675.00
Ask: 676.00
Change: 0.50 (0.07%)
Spread: 1.00 (0.148%)
Open: 674.00
High: 678.50
Low: 672.50
Prev. Close: 673.50
TATE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

3 Apr 2014 07:00

3 April 2014 – Tate & Lyle PLC

STATEMENT ON ENTERING CLOSE PERIOD

In accordance with our usual practice, Tate & Lyle PLC issues the following update for the year ended 31 March 2014 ahead of the announcement of full year results on 29 May 2014.

In line with the guidance issued in our interim management statement on 13 February 2014, we continue to expect Group adjusted profit before tax for the year ended 31 March 2014, at constant rates of exchange1, to be broadly in line with the comparative period.

FULL YEAR OPERATING PERFORMANCE – CONTINUING OPERATIONS

In Speciality Food Ingredients, we continue to expect both volume and sales growth to be in line with the wider speciality food ingredients market, with strong volume growth in emerging markets and Europe partially offset by the US. As expected, operating profit growth in this division has been held back by the more competitive market for SPLENDA® Sucralose.

Within Bulk Ingredients, we continue to expect operating profit for the full year to be lower than the comparative period as a result of the soft beverage season in the US, which reduced demand for liquid corn sweeteners, and lower returns from co-products. The protracted severe cold weather in the US has also held back the performance of this division somewhat in the final quarter, despite the actions taken by our manufacturing and supply chain teams who succeeded in partially mitigating the full impact of this on our operations.

BALANCE SHEET

As noted in the February interim management statement, the payment for new crop corn held in our silos has resulted in a net cash outflow in the final quarter. As a result, net debt at 31 March 2014 will, as expected, be higher than the level reported at 31 December 2013 (£253 million).

END

1 Assuming an average USD:GBP rate of 1.59 for the financial year ending 31 March 2014, we estimate that the impact of exchange translation will be around -1% on our adjusted profit before tax of £327 million reported in the year to 31 March 2013

Conference call:

A conference call will be held today at 8:00am BST, hosted by Javed Ahmed, Chief Executive and Tim Lodge, Chief Financial Officer. Participants are requested to dial in at least 10 minutes before the commencement of the call.

Dial in details are as follows:

Standard International Access: +44 (0) 20 3003 2666Password: Tate & LyleUK replay number: +44 (0)20 8196 1998International replay numbers: http://www.meetingzone.com/en-GB/replaydialinnumbers.aspxReplay access PIN: 6977674

A replay of this call will be available after the end of the live call for 14 days.

For more information contact Tate & Lyle PLC:

Mathew Wootton, Group VP, Investor and Media RelationsTel: +44 (0) 20 7257 2110 or Mobile: +44 (0) 7500 100 320Email: Investor.Relations@tateandlyle.com

Nick Hasell, FTI ConsultingTel: +44 (0) 20 3727 1340 or Mobile: +44 (0) 7825 523 383

About Tate & Lyle:

Tate & Lyle is a global provider of ingredients and solutions to the food, beverage and other industries, operating from over 30 production facilities around the world.

Tate & Lyle operates through two global business units, Speciality Food Ingredients and Bulk Ingredients, supported by the Innovation and Commercial Development group. The Group's strategy is to become the leading global provider of Speciality Food Ingredients through a disciplined focus on growth, and by driving Bulk Ingredients for sustained cash generation to fuel this growth.

Speciality Food Ingredients consists of three platforms: Texturants, which includes speciality starches and stabilisers; Sweeteners, which comprises nutritive sweeteners and our range of no-calorie sweeteners including SPLENDA® Sucralose; and our Health and Wellness portfolio which includes speciality fibres and our salt-reduction offering. Additionally, our food systems business provides a wide variety of blended ingredient solutions.

Tate & Lyle Bulk Ingredients includes bulk sweeteners, industrial starches and fermentation products (primarily acidulants). Corn co-products from both divisions are primarily sold as animal feed.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2013, Tate & Lyle sales totalled £3.3 billion. http://www.tateandlyle.com.

SPLENDA® is a trademark of McNeil Nutritionals, LLC.

Copyright Business Wire 2014

Date   Source Headline
15th Jun 20124:43 pmBUSTransaction in Own Shares
15th Jun 20122:17 pmBUSHolding(s) in Company
8th Jun 20124:50 pmBUSTransaction in Own Shares
6th Jun 201211:48 amBUSHolding(s) in Company
1st Jun 20126:02 pmBUSDirector/PDMR Shareholding
1st Jun 20125:59 pmBUSTransaction in Own Shares
1st Jun 201211:32 amBUSTotal Voting Rights
31st May 20124:43 pmBUSHolding(s) in Company
31st May 20127:00 amBUSFinal Results
21st May 20124:47 pmBUSHolding(s) in Company
11th May 20124:39 pmBUSTransaction in Own Shares
9th May 20124:46 pmBUSTransaction in Own Shares
1st May 201212:11 pmBUSTotal Voting Rights
20th Apr 20127:00 amBUSDisposal
19th Apr 201212:57 pmBUSAdditional Listing
16th Apr 201211:07 amBUSHolding(s) in Company
13th Apr 201212:15 pmBUSHolding(s) in Company
5th Apr 20125:45 pmBUSTransaction in Own Shares
5th Apr 201211:47 amBUSHolding(s) in Company
2nd Apr 20125:13 pmBUSTransaction in Own Shares
2nd Apr 201210:57 amBUSTotal Voting Rights
30th Mar 20124:42 pmBUSHolding(s) in Company
30th Mar 20127:00 amBUSTrading Statement
27th Mar 20126:13 pmBUSHolding(s) in Company
13th Mar 20129:57 amBUSDirector/PDMR Shareholding
8th Mar 20125:36 pmBUSTransaction in Own Shares
7th Mar 20125:07 pmBUSTransaction in Own Shares
6th Mar 20125:04 pmBUSTransaction in Own Shares
5th Mar 20125:07 pmBUSTransaction in Own Shares
1st Mar 20125:14 pmBUSTransaction in Own Shares
1st Mar 20129:23 amBUSTotal Voting Rights
22nd Feb 20129:20 amBUSDirectorate Change
20th Feb 20125:03 pmBUSTransaction in Own Shares
16th Feb 20123:34 pmBUSDirector/PDMR Shareholding
15th Feb 20125:05 pmBUSTransaction in Own Shares
10th Feb 201210:20 amBUSDirector Declaration
9th Feb 20127:00 amBUSInterim Management Statement
6th Feb 20124:50 pmBUSHolding(s) in Company
1st Feb 201210:17 amBUSTotal Voting Rights
30th Jan 20121:46 pmBUSHolding(s) in Company
10th Jan 20123:27 pmBUSDirector/PDMR Shareholding
9th Jan 20124:12 pmBUSTransaction in Own Shares
3rd Jan 20124:25 pmBUSBlocklisting Interim Review
3rd Jan 201210:45 amBUSTotal Voting Rights
20th Dec 201111:01 amBUSHolding(s) in Company
14th Dec 20114:59 pmBUSTransaction in Own Shares
14th Dec 20113:13 pmBUSHolding(s) in Company
13th Dec 20115:28 pmBUSTransaction in Own Shares
12th Dec 20115:34 pmBUSTransaction in Own Shares
9th Dec 20115:49 pmBUSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.